REDEFINE 2: CagriSema Phase 3 trial (NCT05394519)
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 1,200
- actual
- Start
- 1 Feb 2023 (actual)
- Primary completion
- 28 Jan 2025 (actual)
- Sponsor
- Novo Nordisk A/S
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| CagriSema | Experimental | Drug: Cagrilintide; Drug: Semaglutide | Cagrilintide + semaglutide once weekly |
| Placebo | Placebo comparator | Drug: Placebo cagrilintide; Drug: Placebo semaglutide | Placebo cagrilintide + semaglutide once weekly |
Primary endpoint
| Measure | Time frame |
|---|---|
| Relative change in body weight | From baseline (week 0) to end of treatment (week 68) |
| Achievement of greater than or equal to (≥) 5% weight reduction | From baseline (week 0) to end of treatment (week 68) |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Achievement of ≥ 20% weight reduction | From baseline (week 0) to end of treatment (week 68) |
| Relative change in body weight | From baseline (week 0) to week 20 |
| Change in waist circumference | From baseline (week 0) to end of treatment (week 68) |
| Change in Glycated Haemoglobin (HbA1c) | From baseline (week 0) to end of treatment (week 68) |
| Change in Systolic Blood Pressure (SBP) | From baseline (week 0) to end of treatment (week 68) |
| Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score | From baseline (week 0) to end of treatment (week 68) |
| Change in Short Form-36 Version 2.0 Health Survey Acute (SF-36v2 Acute) Physical Functioning score | From baseline (week 0) to end of treatment (week 68) |
| Change in body weight | From baseline (week 0) to end of treatment (week 68) |
| Change in body mass index (BMI) | From baseline (week 0) to end of treatment (week 68) |
| Improvement in weight category (BMI, underweight below 18.5, normal weight 18.5 to below 25, overweight 25.0 to below 30, obesity class I 30 to below 35, obesity class II 35 to below 40, obesity class III above 40) | From baseline (week 0) to end of treatment (week 68) |
| Achievement of HbA1c less than or equal to (≤) 6.5% | At end of treatment (week 68) |
| Change in Fasting Plasma Glucose (mmol/L) | From baseline (week 0) to end of treatment (week 68) |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
The REDEFINE 2 paper in adults with obesity and type 2 diabetes
Adults with a BMI of 27 or more and HbA1c of 7 to 10% were assigned 3:1 to once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo for 68 weeks, alongside lifestyle intervention.[2]
Body weight changed by -13.7% with the combination and -3.4% with placebo, an estimated difference of -10.4 percentage points (95% CI -11.2 to -9.5).[2]
An HbA1c of 6.5% or less was reached by 73.5% of the combination group and 15.9% of the placebo group.[2]
Gastrointestinal adverse events were reported by 72.5% of the combination group and 34.4% of the placebo group.[2]
Sources
- 1Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
Found an error? Report a correction.